Gene Forum welcomes experts in promoting the progression of gene therapy to its Advisory Committee
25 June 2024: Tristan Jervis, Founder and Managing Director of Impact Shine Communications (www.impactshinecommunications.com), who has an established record of promoting the progression of CGT, is honoured to join the Advisory Committee of the Gene Forum, which provides a platform for further advancing the field of gene therapy.
As the cell and gene therapy (CGT) landscape evolves, analytical technologies and capabilities are developing just as rapidly. With the goal of providing a platform for scientists, researchers and industry leaders to converge and explore the field’s multifaceted dimensions, the Gene Forum is organising a cutting-edge conference, focused on key gene therapy issues, trends and analysis, on December 4-6, 2024 in Paris, France (genetherapyconference.com/).
The 2nd International Human Gene Therapy Conference 2024 is guided by an Advisory Committee comprising experts from various disciplines in the CGT arena. These Advisors ensure the conference provides a platform for exchanging fresh findings and trends in gene therapy, encouraging collaboration among pivotal figures and advancing the sector overall.
Among other recent additions, Tristan Jervis, Founder and Managing Director of Impact Shine Communications (impactshinecommunications.com), has joined this board of advisors. Mr Jervis has a 23-year pedigree in supporting companies with strategic communications and public affairs needs in life science & healthcare sectors, including CGT, biopharma, biotech, specialist devices and diagnostics. He brings to the Gene Forum’s Advisory Committee his expertise in directing and implementing strategic communications campaigns across the industry spectrum and a broad understanding of the industry’s challenges and issues.
“I am proud and honoured to have been invited to this Advisory Committee, and I look forward to leveraging my extensive experience and network in the field to make it an overwhelming success,” said Mr Jervis. “I would encourage you to attend the 2nd International Human Gene Therapy Conference 2024 to stay informed about the latest research in, and diverse perspectives of, gene therapy. I am particularly excited about helping to identify the best experts and key opinion leaders for the speaker programme, and making sure that the conference covers important new considerations and challenges.”
The Gene Forum 2024 conference organisers expect attendance from across the world, with representatives from gene therapy discovery and development, manufacturing, quality control and validation, regulatory affairs, clinical administration and patient advocacy. Stakeholders from across the entire supply chain are expected to attend and discuss new developments and solutions to current issues, effectively advancing the gene therapy sector.
“Our goal is to connect different stakeholders who can work together to ensure the successful development and delivery of gene therapy products”, said Deekshitha G, Conference Producer. “We are delighted that Mr Jervis has agreed to join the Advisory Committee, as his extensive network and knowledge in this field will bring tremendous value in helping us make this event a success.”
Abstract submissions are welcome – visit genetherapyconference.com/ to submit your paper by 30th July 2024, and sign up before 19th August 2024 for an early-bird discount on your registration fee.
We look forward to seeing you in Paris. À bientôt!
